

Product	Mechanism	Indication	Phase 1	Phase 2	Phase 3	Countries Where Registered
Zanubrutinib	BTK inhibitor	CLL/SLL				US, EU (CLL), and other regions
		WM				US, EU, and other regions
		R/R FL				US, EU, and other regions
		R/R MZL				US, EU, and other regions
		TN MCL				
		R/R MCL				US and other regions
		R/R DLBCL with CD79B				
		Previously treated B-cell malignancies				
Zanubrutinib (Immunology & Inflammation)	BTK inhibitor	Primary membranous nephropathy				
		Lupus nephritis				
Sonrotoclax	BCL2 inhibitor	TN CLL <sup>a</sup>				
		R/R WM				
		R/R CLL				
		R/R MCL				
		R/R MM with t(11;14)				
		AML/MDS				
		B-cell malignancies				
BGB-16673	BTK-targeted CDAC	B-cell malignancies				
		R/R MCL and R/R CLL				
BGB-21447	BCL2 inhibitor	B-cell malignancies				
Tislelizumab	anti-PD-1	R/R cHL				China
Ociperlimab	anti-TIGIT	R/R DLBCL				

Safety and efficacy have not been established for investigational products and/or uses.

**Abbreviations:** AML, acute myeloid leukemia; BCL2, B-cell lymphoma 2; BTK, Bruton tyrosine kinase; CD79B, cluster of differentiation 79B; CDAC, chimeric degradation activating compound; cHL, classical Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MDS, myelodysplastic syndromes; MM, multiple myeloma; MZL, marginal zone lymphoma; PD-1, programmed cell death protein 1; R/R, recurrent/refractory; SLL, small lymphocytic lymphoma; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; TN, treatment naive; WM, Waldenström macroglobulinemia.

<sup>a</sup>In combination with zanubrutinib.

**FOR MORE INFORMATION ON APPROVED USES IN YOUR REGION/COUNTRY, CONTACT A BEIGENE REPRESENTATIVE OR MEDICALINFORMATION@BEIGENE.COM**

0120-BGB-A283-MRC-001

**May 2024**

Product	Mechanism	Indication	Phase 1	Phase 2	Phase 3	Countries Where Registered
Tislelizumab	anti-PD-1	1L NonSq NSCLC, 1L Sq. NSCLC, 2/3L NSCLC				EU and other regions
		1L GC/GEJC				China
		1L ESCC				China
		2L ESCC				US, EU, and other regions
		1L NPC				China
		1L HCC, 2/3L HCC				China
		1L UBC				
		LA ESCC				
		Neo/adj NSCLC				
		1L ES-SCLC				
		NSCLC (subcutaneous formulation)				
Ociperlimab	anti-TIGIT	1L PD-L1 high NSCLC				
		Solid tumors				
BG-68501 <sup>1</sup>	CDK2 inhibitor	BC and solid tumors				
BGB-43395	CDK4 inhibitor	BC and solid tumors				
BG-C9074 <sup>2</sup>	B7H4-ADC	BC and solid tumors				

Safety and efficacy have not been established for investigational products and/or uses.

**Abbreviations:** ADC, antibody-drug conjugate; ADD: BC, breast cancer; CDK, cyclin-dependent kinase; CRC, colorectal cancer; ESCC, esophageal squamous cell carcinoma; ES-SCLC, extensive-stage small cell lung cancer; GC, gastric cancer; GEJC, gastroesophageal junction carcinoma; HCC, hepatocellular carcinoma; 1L, first line; LA, locally advanced; NPC, nasopharyngeal carcinoma; NonSq, non-squamous; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; SCLC, small cell lung cancer; Sq, squamous; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; UBC, urothelial bladder cancer.

<sup>1</sup>Ensem collaboration; BeiGene has global rights.

<sup>2</sup>DualityBio collaboration; BeiGene has global rights.

Product	Mechanism	Indication	Phase 1	Phase 2	Phase 3	Countries Where Registered
LBL-007 <sup>1</sup>	anti-LAG3	MSS-CRC				
		1L ESCC				
Surzebiclimab	anti-TIM3	1L HNSCC				
Umbrella	IO combinations	1L NSCLC <sup>a</sup>				
		Neo/adj NSCLC <sup>a</sup>				
		2L+ NSCLC <sup>a</sup>				
		1L HNSCC <sup>a</sup>				
Zanidatamab <sup>2</sup>	anti-HER2 BsAb	2L HER2+ BTC				
		1L HER2+ GEA				
		1L HER2+ mBC/GC				
BGB-A445	anti-OX40	Melanoma, RCC, UC				
BGB-15025	HPK1 inhibitor	Solid tumors				
BGB-26808	HPK1 inhibitor	Solid tumors				
BGB-24714	SMAC mimetic	Solid tumors				
BGB-30813	DGKζ inhibitor	Solid tumors				
BGB-A3055	anti-CCR8	Solid tumors				

Safety and efficacy have not been established for investigational products and/or uses.

**Abbreviations:** 1L, first line; 2L, second line; BC, breast cancer; BsAb, bispecific antibody; BTC, biliary tract cancer; CCR8, the C-C motif chemokine receptor 8; CRC, colorectal cancer; DGKζ, diacylglycerol kinase ζ; GC, gastric cancer; GEA, gastroesophageal adenocarcinomas; HER2, human epidermal growth factor receptor 2; HNSCC, head and neck squamous cell carcinoma; HPK1, hematopoietic progenitor kinase 1; LAG3, lymphocyte activation gene 3; LS-SCLC, limited-stage small cell lung cancer; mBC, metastatic breast cancer; MSS, microsatellite stability; OX40, a member of the tumor necrosis factor (TNF) receptor family, also known as CD134; RCC, renal cell carcinoma; R/R, recurrent/refractory; SCLC, small cell lung cancer; SMAC, second mitochondria-derived activator of caspase; TIM3, T-cell immunoglobulin domain and mucin domain 3; UC, urothelial carcinoma.

<sup>a</sup>May include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor.

<sup>1</sup>Leads Biolabs collaboration; BeiGene has ex-China commercial rights.

<sup>2</sup>Zymeworks/Jazz collaboration; BeiGene has APAC/ex Japan, AU, and NZ commercial rights.

Product	Mechanism	Indication	Phase 1	Phase 2	Phase 3	Countries Where Registered
BGB-10188	PI3Kδ inhibitor	Solid tumors				
Pamiparib	PARP 1/2 inhibitor	2L MTx gBRCAm PSOC				
		Advanced ovarian cancer				China
Taratamab <sup>1</sup>	DLL3 x CD3	2L SCLC				US
		1L-ES-SCLC (initiation activities)				
		LS-SCLC (initiation activities)				
		3L+ SCLC				US
Xaluritamig <sup>1</sup>	STEAP1 x CD3	mCRPC				
Blinatumomab <sup>1</sup>	CD3 X CD19	Pediatric R/R BP-ALL (initiation activities)				
Goserelin microspheres <sup>2</sup>	GnRH agonist	Breast and prostate cancer				China
BGB-C354	B7H3-ADC	Lung and GI cancers (preclinical)	Planned for 2024			
BGB-B3227	MUC1 x CD16A BsAb	Lung, GI and BC (preclinical)	Planned for 2024			
BG-C477	CEA-ADC	Lung and GI cancers (preclinical)	Planned for 2024			
BGB-53038	PanKRAS inhibitor 2G	Lung and GI cancers (preclinical)	Planned for 2024			
BG-C137	FGFR2b ADC	GI cancer (preclinical)	Planned for 2024			
BGB-58067	PRMT5 inhibitor	Lung and GI cancers (preclinical)	Planned for 2024			
BG-60366	EGFR-targeted CDAC	Lung cancer (preclinical)	Planned for 2024			

Safety and efficacy have not been established for investigational products and/or uses.

**Abbreviations:** 1L, first line; 3L, third line; ADC, antibody-drug conjugate; BC, breast cancer; BsAb, bispecific antibody; BTC, biliary tract cancer; BP-ALL, B-cell precursor acute lymphoblastic leukemia; CD3, cluster of differentiation 3; CD19, cluster of differentiation 19; DLL3, delta-like ligand 3; ES-SCLC, extensive-stage small cell lung cancer; gBRCAm, germline BRCA mutation; GI, gastrointestinal; GnRH, gonadotropin-releasing hormone; HER2, human epidermal growth factor receptor 2; 2L, second line; LS-SCLC, limited-stage small cell lung cancer; mBC, metastatic breast cancer; mCRPC, metastatic castration-resistant prostate cancer; MTx, maintenance treatment; PI3Kδ, phosphoinositide 3-kinase-δ; PARP 1/2, poly (ADP-ribose) polymerase 1 and 2; PSOC, platinum-sensitive ovarian cancer; R/R, recurrent/refractory; SCLC, small cell lung cancer; STEAP1, six-transmembrane epithelial antigen of the prostate 1.

<sup>1</sup>Amgen collaboration; BeiGene has China commercial rights.

<sup>2</sup>Luye collaboration; BeiGene has China rights.